Delivery Order SPE2DB24D1021-SPE2DB25FFAMQ
- Not listed
- The Defense Logistics Agency (DLA) awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/milliliter pharmaceutical product on September 4, 2025, with completion expected by September 5, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $279,751.97 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 150 MG/ML in pen/milliliter formulation. This is a firm fixed price contract with no set-aside designation, executed as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is set to be completed by September 9, 2025, with fulfillment occurring at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of SKYRIZI 150 mg/ml in pen/ml formulation, with a ceiling value of $24,342.14. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,515.57 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen/milliliter on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $134,643.50 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL pen medication. This firm fixed price delivery order, issued on September 9, 2025, with completion scheduled for September 10, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,842.74 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML PENFILL, a pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and carries no set-aside designation, indicating it was awarded through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, the company's headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $14,794.36 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation, featuring an ultimate completion date of July 31, 2025. The contract was executed on July 30, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/mL pharmaceutical product. The contract, awarded on September 2, 2025, with completion targeted for September 3, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL in pen form, valued at $24,893.20 under a firm fixed-price contract awarded on August 24, 2025. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion master contract running through December 2026 that serves as a comprehensive global pharmaceutical...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAMQDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,093.66 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML in pen/milliliter format. The contract is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and was awarded on September 10, 2025. The contract carries no set-aside designation and represents a competitively awarded transaction. Performance will be fulfilled from AmerisourceBergen Drug Corp's Conshohocken, Pennsylvania facility, the company's corporate headquarters and primary distribution center. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling value through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement across the Defense Health Agency and other military healthcare systems. The company's broad IDC vehicle enables the supply of specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. SKYRIZI is a biologic medication used in dermatological and rheumatological applications, reflecting the company's role in delivering specialized pharmaceutical products to support federal healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.1k | 9/10/25 |